185 related articles for article (PubMed ID: 22315494)
1. CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.
Aranaz P; Hurtado C; Erquiaga I; Miguéliz I; Ormazábal C; Cristobal I; García-Delgado M; Novo FJ; Vizmanos JL
Haematologica; 2012 Aug; 97(8):1234-41. PubMed ID: 22315494
[TBL] [Abstract][Full Text] [Related]
2. TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.
Martínez-Avilés L; Besses C; Álvarez-Larrán A; Torres E; Serrano S; Bellosillo B
Ann Hematol; 2012 Apr; 91(4):533-41. PubMed ID: 21904853
[TBL] [Abstract][Full Text] [Related]
3. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.
Grand FH; Hidalgo-Curtis CE; Ernst T; Zoi K; Zoi C; McGuire C; Kreil S; Jones A; Score J; Metzgeroth G; Oscier D; Hall A; Brandts C; Serve H; Reiter A; Chase AJ; Cross NC
Blood; 2009 Jun; 113(24):6182-92. PubMed ID: 19387008
[TBL] [Abstract][Full Text] [Related]
4. SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.
Koren-Michowitz M; Gery S; Tabayashi T; Lin D; Alvarez R; Nagler A; Koeffler HP
Br J Haematol; 2013 Jun; 161(6):811-20. PubMed ID: 23590807
[TBL] [Abstract][Full Text] [Related]
5. Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases.
Schnittger S; Bacher U; Alpermann T; Reiter A; Ulke M; Dicker F; Eder C; Kohlmann A; Grossmann V; Kowarsch A; Kern W; Haferlach C; Haferlach T
Haematologica; 2012 Dec; 97(12):1890-4. PubMed ID: 22733026
[TBL] [Abstract][Full Text] [Related]
6. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms.
Olcaydu D; Rumi E; Harutyunyan A; Passamonti F; Pietra D; Pascutto C; Berg T; Jäger R; Hammond E; Cazzola M; Kralovics R
Haematologica; 2011 Mar; 96(3):367-74. PubMed ID: 21173100
[TBL] [Abstract][Full Text] [Related]
7. A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes.
Aranaz P; Ormazábal C; Hurtado C; Erquiaga I; Calasanz MJ; García-Delgado M; Novo FJ; Vizmanos JL
Cancer Genet Cytogenet; 2010 May; 199(1):1-8. PubMed ID: 20417861
[TBL] [Abstract][Full Text] [Related]
8. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Tefferi A
Leukemia; 2010 Jun; 24(6):1128-38. PubMed ID: 20428194
[TBL] [Abstract][Full Text] [Related]
9. Mutational status of myeloproliferative neoplasms.
Rumi E; Elena C; Passamonti F
Crit Rev Eukaryot Gene Expr; 2010; 20(1):61-76. PubMed ID: 20528738
[TBL] [Abstract][Full Text] [Related]
10. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
Makishima H; Cazzolli H; Szpurka H; Dunbar A; Tiu R; Huh J; Muramatsu H; O'Keefe C; Hsi E; Paquette RL; Kojima S; List AF; Sekeres MA; McDevitt MA; Maciejewski JP
J Clin Oncol; 2009 Dec; 27(36):6109-16. PubMed ID: 19901108
[TBL] [Abstract][Full Text] [Related]
11. Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis.
Cappetta M; Pérez V; Zubillaga MN; Elizondo V; Manrique G; Prosper I; Boschi S; Bonomi R; Pomoli S; Díaz L; Martínez L; Uriarte MR
Int J Lab Hematol; 2013 Feb; 35(1):e4-5. PubMed ID: 23062104
[No Abstract] [Full Text] [Related]
12. Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow.
Schnittger S; Bacher U; Eder C; Dicker F; Alpermann T; Grossmann V; Kohlmann A; Kern W; Haferlach C; Haferlach T
Haematologica; 2012 Oct; 97(10):1582-5. PubMed ID: 22511494
[TBL] [Abstract][Full Text] [Related]
13. Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders.
Naramura M; Nadeau S; Mohapatra B; Ahmad G; Mukhopadhyay C; Sattler M; Raja SM; Natarajan A; Band V; Band H
Oncotarget; 2011 Mar; 2(3):245-50. PubMed ID: 21422499
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant mice.
Duyvestyn JM; Taylor SJ; Dagger SA; Orandle M; Morse HC; Thien CB; Langdon WY
PLoS One; 2014; 9(4):e94717. PubMed ID: 24718698
[TBL] [Abstract][Full Text] [Related]
15. MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
Ma W; Zhang X; Wang X; Zhang Z; Yeh CH; Uyeji J; Albitar M
Diagn Mol Pathol; 2011 Mar; 20(1):34-9. PubMed ID: 21326037
[TBL] [Abstract][Full Text] [Related]
16. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.
Sanada M; Suzuki T; Shih LY; Otsu M; Kato M; Yamazaki S; Tamura A; Honda H; Sakata-Yanagimoto M; Kumano K; Oda H; Yamagata T; Takita J; Gotoh N; Nakazaki K; Kawamata N; Onodera M; Nobuyoshi M; Hayashi Y; Harada H; Kurokawa M; Chiba S; Mori H; Ozawa K; Omine M; Hirai H; Nakauchi H; Koeffler HP; Ogawa S
Nature; 2009 Aug; 460(7257):904-8. PubMed ID: 19620960
[TBL] [Abstract][Full Text] [Related]
17. A point mutation of zebrafish c-cbl gene in the ring finger domain produces a phenotype mimicking human myeloproliferative disease.
Peng X; Dong M; Ma L; Jia XE; Mao J; Jin C; Chen Y; Gao L; Liu X; Ma K; Wang L; Du T; Jin Y; Huang Q; Li K; Zon LI; Liu T; Deng M; Zhou Y; Xi X; Zhou Y; Chen S
Leukemia; 2015 Dec; 29(12):2355-65. PubMed ID: 26104663
[TBL] [Abstract][Full Text] [Related]
18. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
Reindl C; Quentmeier H; Petropoulos K; Greif PA; Benthaus T; Argiropoulos B; Mellert G; Vempati S; Duyster J; Buske C; Bohlander SK; Humphries KR; Hiddemann W; Spiekermann K
Clin Cancer Res; 2009 Apr; 15(7):2238-47. PubMed ID: 19276253
[TBL] [Abstract][Full Text] [Related]
19. Molecular aspects of myeloproliferative neoplasms.
Delhommeau F; Jeziorowska D; Marzac C; Casadevall N
Int J Hematol; 2010 Mar; 91(2):165-73. PubMed ID: 20186505
[TBL] [Abstract][Full Text] [Related]
20. [JAK2-V617F mutation in patients with myeloproliferative neoplasms: association with FLT3-ITD mutation].
Spasovski V; Tosić N; Kostić T; Pavlović S; Colović M
Srp Arh Celok Lek; 2010; 138(9-10):614-8. PubMed ID: 21180092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
